Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 23, 2024

SELL
$83.81 - $99.0 $670 - $792
-8 Reduced 9.09%
80 $6,000
Q2 2023

Jul 11, 2023

BUY
$86.68 - $100.3 $693 - $802
8 Added 10.0%
88 $7,000
Q3 2021

Oct 18, 2021

SELL
$74.77 - $85.47 $2,467 - $2,820
-33 Reduced 29.2%
80 $6,000
Q2 2021

Jul 12, 2021

SELL
$75.51 - $84.79 $1,434 - $1,611
-19 Reduced 14.39%
113 $9,000
Q1 2021

Apr 21, 2021

SELL
$74.73 - $90.69 $4.2 Million - $5.09 Million
-56,157 Reduced 99.77%
132 $10,000
Q4 2020

Jan 08, 2021

SELL
$72.61 - $90.2 $45,090 - $56,014
-621 Reduced 1.09%
56,289 $4.28 Million
Q3 2020

Oct 06, 2020

BUY
$71.87 - $131.03 $711,369 - $1.3 Million
9,898 Added 21.05%
56,910 $4.33 Million
Q2 2020

Jul 10, 2020

BUY
$79.55 - $124.22 $66,265 - $103,475
833 Added 1.8%
47,012 $5.8 Million
Q1 2020

Apr 07, 2020

BUY
$71.37 - $96.85 $286,050 - $388,174
4,008 Added 9.5%
46,179 $3.9 Million
Q4 2019

Jan 15, 2020

BUY
$64.27 - $86.37 $302,197 - $406,111
4,702 Added 12.55%
42,171 $3.57 Million
Q3 2019

Oct 10, 2019

BUY
$67.4 - $85.11 $563,531 - $711,604
8,361 Added 28.72%
37,469 $2.53 Million
Q2 2019

Jul 16, 2019

BUY
$80.35 - $93.9 $2.11 Million - $2.47 Million
26,297 Added 935.5%
29,108 $2.49 Million
Q1 2019

Apr 11, 2019

BUY
$84.2 - $98.62 $236,686 - $277,220
2,811 New
2,811 $250,000
Q3 2018

Oct 11, 2018

SELL
$93.92 - $105.72 $28,176 - $31,716
-300 Closed
0 $0
Q2 2018

Aug 09, 2018

BUY
$76.01 - $99.03 $22,803 - $29,709
300 New
300 $28,000

Others Institutions Holding BMRN

About BIOMARIN PHARMACEUTICAL INC


  • Ticker BMRN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,824,000
  • Market Cap $12.1B
  • Description
  • BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...
More about BMRN
Track This Portfolio

Track Gradient Investments LLC Portfolio

Follow Gradient Investments LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gradient Investments LLC, based on Form 13F filings with the SEC.

News

Stay updated on Gradient Investments LLC with notifications on news.